⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AIM News
AIM ImmunoTech Inc.
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
globenewswire.com
AIM
BULL
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
globenewswire.com
AIM
CIRI Announces 2026 Annual General Meeting Voting Results
globenewswire.com
AGI
TD
IMO
MFI
MX
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
globenewswire.com
AIM
Form 8-K
sec.gov
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
globenewswire.com
AIM
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
globenewswire.com
AIM
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness
globenewswire.com
AIM